Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study

By Yohann Loriot, MD, PhD, Vadim Koshkin, MD - Last Updated: August 1, 2023

Yohann Loriot, MD, PhD, Gustave Roussy Cancer Institute, and Vadim Koshkin, MD, University of California, San Francisco, summarize the latest data presented on cohort 1 of the THOR study, which compared erdafitinib and chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.

View more ASCO 2023 videos.

Advertisement
Advertisement